W. Roberts Eiry's Insider Trades & SAST Disclosures
W. Roberts Eiry's most recent trade in Neurocrine Biosciences, Inc. was a trade of 43,261 Stock Option done . Disclosure was reported to the exchange on Feb. 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern W. Roberts Eiry.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 43,261 | 43,261 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 8,108 | 8,108 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,113 | 35,366 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,113 | 4,227 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,372 | 36,140 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,372 | 4,115 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,120 | 35,372 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 1,120 | 3,363 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 116.90 per share. | 12 Feb 2025 | 1,114 | 34,252 (0%) | 0% | 116.9 | 130,232 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 116.74 per share. | 12 Feb 2025 | 604 | 34,768 (0%) | 0% | 116.7 | 70,510 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 115.04 per share. | 12 Feb 2025 | 500 | 35,640 (0%) | 0% | 115.0 | 57,521 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 1,860 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2025 | 1,860 | 34,233 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 118.22 per share. | 08 Feb 2025 | 980 | 33,253 (0%) | 0% | 118.2 | 115,853 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,769 | 2,769 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 2,769 | 33,830 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 152.80 per share. | 31 Jan 2025 | 1,457 | 32,373 (0%) | 0% | 152.8 | 222,636 | Common Stock |
| Neurocrine Biosciences, Inc. | W. Roberts Eiry | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2024 | 27,770 | 27,770 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Roberts Eiry W. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2024 | 5,487 | 5,487 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.81 per share. | 08 Nov 2024 | 5,140 | 28,856 (0%) | 0% | 77.8 | 399,943 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 5,140 | 0 | - | - | Incentive Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 1,233 | 0 | - | - | Incentive Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.05 per share. | 08 Nov 2024 | 1,233 | 30,089 (0%) | 0% | 81.1 | 99,935 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 971 | 0 | - | - | Incentive Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 102.90 per share. | 08 Nov 2024 | 971 | 31,060 (0%) | 0% | 102.9 | 99,916 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 1 | 1,265 | - | - | Incentive Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.00 per share. | 08 Nov 2024 | 1 | 31,061 (0%) | 0% | 79 | 79 | Common Stock |
| Amicus Therapeutics Inc | Eiry W. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 42,467 | 42,467 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Eiry W. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 11,847 | 55,861 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 22,529 | 22,529 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Roberts Eiry W. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 4,483 | 4,483 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Roberts W. Eiry | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 132.96 per share. | 13 Feb 2024 | 1,114 | 23,716 (0%) | 0% | 133.0 | 148,122 | Common Stock |
| Neurocrine Biosciences, Inc. | W. Roberts Eiry | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 142.24 per share. | 06 Feb 2024 | 1,121 | 21,837 (0%) | 0% | 142.2 | 159,446 | Common Stock |
| Neurocrine Biosciences, Inc. | W. Roberts Eiry | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 134.21 per share. | 06 Feb 2024 | 980 | 22,717 (0%) | 0% | 134.2 | 131,522 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 140.79 per share. | 31 Jan 2024 | 1,457 | 20,832 (0%) | 0% | 140.8 | 205,132 | Common Stock |
| Neurocrine Biosciences, Inc. | W. Eiry Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 126.74 per share. | 22 Dec 2023 | 10,000 | 19,521 (0%) | 0% | 126.7 | 1,267,448 | Common Stock |
| Neurocrine Biosciences, Inc. | Roberts W. Eiry | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2023 | 6,978 | 46,387 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | W. Eiry Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.05 per share. | 12 Dec 2023 | 6,978 | 36,499 (0%) | 0% | 81.1 | 565,567 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 120.30 per share. | 12 Dec 2023 | 6,978 | 29,521 (0%) | 0% | 120.3 | 839,461 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.05 per share. | 12 Dec 2023 | 6,947 | 36,468 (0%) | 0% | 81.0 | 563,054 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry Roberts W. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 120.31 per share. | 12 Dec 2023 | 6,947 | 29,521 (0%) | 0% | 120.3 | 835,779 | Common Stock |
| Neurocrine Biosciences, Inc. | Roberts W. Eiry | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2023 | 6,947 | 39,440 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | W. Roberts Eiry | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 38,722 | 12,742 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry Roberts W. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.81 per share. | 07 Dec 2023 | 38,722 | 68,243 (0%) | 0% | 77.8 | 3,012,959 | Common Stock |
| Neurocrine Biosciences, Inc. | Roberts Eiry W. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 120.37 per share. | 07 Dec 2023 | 38,722 | 29,521 (0%) | 0% | 120.4 | 4,661,118 | Common Stock |
| Neurocrine Biosciences, Inc. | W. Roberts Eiry | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 07 Dec 2023 | 14,140 | 43,661 (0%) | 0% | 79.0 | 1,117,343 | Common Stock |
| Neurocrine Biosciences, Inc. | W. Eiry Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 120.37 per share. | 07 Dec 2023 | 14,140 | 29,521 (0%) | 0% | 120.4 | 1,702,053 | Common Stock |
| Neurocrine Biosciences, Inc. | Roberts Eiry W. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 14,140 | 60,005 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.81 per share. | 07 Dec 2023 | 12,742 | 42,263 (0%) | 0% | 77.8 | 991,455 | Common Stock |
| Neurocrine Biosciences, Inc. | Roberts Eiry W. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 12,742 | 0 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 120.37 per share. | 07 Dec 2023 | 12,742 | 29,521 (0%) | 0% | 120.4 | 1,533,774 | Common Stock |
| Neurocrine Biosciences, Inc. | Roberts Eiry W. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.05 per share. | 07 Dec 2023 | 11,775 | 41,296 (0%) | 0% | 81.1 | 954,364 | Common Stock |
| Neurocrine Biosciences, Inc. | W. Roberts Eiry | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 11,775 | 53,665 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | W. Eiry Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 120.37 per share. | 07 Dec 2023 | 11,775 | 29,521 (0%) | 0% | 120.4 | 1,417,374 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry Roberts W. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.05 per share. | 07 Dec 2023 | 200 | 29,721 (0%) | 0% | 81.1 | 16,210 | Common Stock |
| Neurocrine Biosciences, Inc. | Roberts W. Eiry | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 200 | 53,465 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 120.16 per share. | 07 Dec 2023 | 200 | 29,521 (0%) | 0% | 120.2 | 24,031 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.05 per share. | 07 Dec 2023 | 100 | 29,621 (0%) | 0% | 81.1 | 8,105 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry Roberts W. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2023 | 100 | 53,365 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 120.00 per share. | 07 Dec 2023 | 100 | 29,521 (0%) | 0% | 120 | 12,000 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2023 | 8,396 | 51,464 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.81 per share. | 06 Dec 2023 | 8,396 | 37,917 (0%) | 0% | 77.8 | 653,293 | Common Stock |
| Neurocrine Biosciences, Inc. | W. Roberts Eiry | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 120.03 per share. | 06 Dec 2023 | 8,396 | 29,521 (0%) | 0% | 120.0 | 1,007,780 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 107.38 per share. | 21 Aug 2023 | 3,198 | 29,521 (0%) | 0% | 107.4 | 343,388 | Common Stock |
| Amicus Therapeutics Inc | Eiry W. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 30,474 | 30,474 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Eiry W. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 8,584 | 44,014 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 103.48 per share. | 24 Apr 2023 | 14,400 | 26,644 (0%) | 0% | 103.5 | 1,490,059 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 52,532 | 52,532 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 8,453 | 8,453 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 102.41 per share. | 06 Feb 2023 | 12,801 | 40,135 (0%) | 0% | 102.4 | 1,310,918 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 102.35 per share. | 06 Feb 2023 | 1,623 | 28,638 (0%) | 0% | 102.3 | 166,114 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 105.80 per share. | 06 Feb 2023 | 1,121 | 27,176 (0%) | 0% | 105.8 | 118,602 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 104.16 per share. | 06 Feb 2023 | 980 | 41,015 (0%) | 0% | 104.2 | 102,072 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 109.99 per share. | 31 Jan 2023 | 1,457 | 26,171 (0%) | 0% | 110.0 | 160,254 | Common Stock |
| Amicus Therapeutics Inc | Eiry W. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 45,423 | 45,423 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Eiry W. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 12,671 | 35,430 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 80.77 per share. | 07 Feb 2022 | 1,623 | 22,741 (0%) | 0% | 80.8 | 131,086 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 80.80 per share. | 07 Feb 2022 | 1,121 | 23,746 (0%) | 0% | 80.8 | 90,574 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 79.52 per share. | 07 Feb 2022 | 980 | 24,625 (0%) | 0% | 79.5 | 77,931 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 75,411 | 75,411 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 11,074 | 11,074 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 74.50 per share. | 10 Jan 2022 | 2,632 | 21,279 (0%) | 0% | 74.5 | 196,088 | Common Stock |
| Amicus Therapeutics Inc | Eiry W. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 40,625 | 40,625 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Eiry W. Roberts | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 22,759 | 22,759 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2021 | 49,049 | 49,049 | - | - | Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 111.06 per share. | 08 Jan 2021 | 2,632 | 15,845 (0%) | 0% | 111.1 | 292,297 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 118.84 per share. | 05 Aug 2020 | 2,257 | 11,446 (0%) | 0% | 118.8 | 268,225 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.81 per share. | 23 Jun 2020 | 5,000 | 14,416 (0%) | 0% | 77.8 | 389,050 | Common Stock |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2020 | 5,000 | 59,860 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences, Inc. | Eiry W. Roberts | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 130.00 per share. | 23 Jun 2020 | 5,000 | 9,416 (0%) | 0% | 130 | 650,000 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges